171 related articles for article (PubMed ID: 34215506)
1. A 25 year perspective on advances in the pathologic assessment and diagnosis of urologic cancers.
Hansel DE
Urol Oncol; 2021 Sep; 39(9):582-594. PubMed ID: 34215506
[TBL] [Abstract][Full Text] [Related]
2. Updates in the Eighth Edition of the Tumor-Node-Metastasis Staging Classification for Urologic Cancers.
Paner GP; Stadler WM; Hansel DE; Montironi R; Lin DW; Amin MB
Eur Urol; 2018 Apr; 73(4):560-569. PubMed ID: 29325693
[TBL] [Abstract][Full Text] [Related]
3. The Genitourinary Pathology Society Update on Classification of Variant Histologies, T1 Substaging, Molecular Taxonomy, and Immunotherapy and PD-L1 Testing Implications of Urothelial Cancers.
Compérat E; Amin MB; Epstein JI; Hansel DE; Paner G; Al-Ahmadie H; True L; Bayder D; Bivalacqua T; Brimo F; Cheng L; Cheville J; Dalbagni G; Falzarano S; Gordetsky J; Guo C; Gupta S; Hes O; Iyer G; Kaushal S; Kunju L; Magi-Galluzzi C; Matoso A; McKenney J; Netto GJ; Osunkoya AO; Pan CC; Pivovarcikova K; Raspollini MR; Reis H; Rosenberg J; Roupret M; Shah RB; Shariat SF; Trpkov K; Weyerer V; Zhou M; Reuter V
Adv Anat Pathol; 2021 Jul; 28(4):196-208. PubMed ID: 34128484
[TBL] [Abstract][Full Text] [Related]
4. Urologic cancer in China.
Pang C; Guan Y; Li H; Chen W; Zhu G
Jpn J Clin Oncol; 2016 Jun; 46(6):497-501. PubMed ID: 27049022
[TBL] [Abstract][Full Text] [Related]
5. A 25-year perspective on the evolution of radiation treatment of urologic cancers.
Hoffman KE; Johnstone P
Urol Oncol; 2021 Sep; 39(9):577-581. PubMed ID: 34325987
[TBL] [Abstract][Full Text] [Related]
6. A 25-year perspective on evaluation and understanding of biomarkers in urologic cancers.
Feldman AS; Lokeshwar V; Lin DW
Urol Oncol; 2021 Sep; 39(9):602-617. PubMed ID: 34315659
[TBL] [Abstract][Full Text] [Related]
7. Potential biomarkers and risk assessment models to enhance the tumor-node-metastasis (TNM) staging classification of urologic cancers.
Darrell CM; Montironi R; Paner GP
Expert Rev Mol Diagn; 2020 Sep; 20(9):921-932. PubMed ID: 32876523
[TBL] [Abstract][Full Text] [Related]
8. Challenges and advances in the diagnosis, biology, and treatment of urothelial upper tract and bladder carcinomas.
Aragon-Ching JB
Urol Oncol; 2017 Jul; 35(7):462-464. PubMed ID: 28625477
[TBL] [Abstract][Full Text] [Related]
9. Impact of the length of time between diagnosis and surgical removal of urologic neoplasms on survival.
Bourgade V; Drouin SJ; Yates DR; Parra J; Bitker MO; Cussenot O; Rouprêt M
World J Urol; 2014 Apr; 32(2):475-9. PubMed ID: 23455886
[TBL] [Abstract][Full Text] [Related]
10. The history of urologic pathology: an overview.
Young RH; Eble JN
Histopathology; 2019 Jan; 74(1):184-212. PubMed ID: 30565309
[TBL] [Abstract][Full Text] [Related]
11. Does solitary- and organ-confined metastasectomy really improve survival in advanced urologic malignancies?
Tonyali S; Yazici S
Int Urol Nephrol; 2016 May; 48(5):671-80. PubMed ID: 26843415
[TBL] [Abstract][Full Text] [Related]
12. Urothelial Carcinoma In Situ (CIS): New Insights.
Akhtar M; Al-Bozom IA; Ben Gashir M; Taha NM; Rashid S; Al-Nabet ADMH
Adv Anat Pathol; 2019 Sep; 26(5):313-319. PubMed ID: 31149909
[TBL] [Abstract][Full Text] [Related]
13. A 25-year perspective on advances in the study of the epidemiology, disparities, and outcomes of urologic cancers.
Psutka SP; Singer EA; Gore J
Urol Oncol; 2021 Sep; 39(9):595-601. PubMed ID: 33934967
[TBL] [Abstract][Full Text] [Related]
14. Surveillance of urothelial carcinoma: stage and grade migration, 1993-2005 and survival trends, 1993-2000.
David KA; Mallin K; Milowsky MI; Ritchey J; Carroll PR; Nanus DM
Cancer; 2009 Apr; 115(7):1435-47. PubMed ID: 19215030
[TBL] [Abstract][Full Text] [Related]
15. Bladder, penile, renal pelvis and testis cancers: A population based analysis of incidence and survival 1977-2013.
Tempo J; Logan C; O'Callaghan M; Kahokehr A; Kichenadasse G; D'Onise K; Foreman D
Cancer Epidemiol; 2020 Apr; 65():101692. PubMed ID: 32151978
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review.
Sanguedolce F; Russo D; Calò B; Cindolo L; Carrieri G; Cormio L
Pathol Res Pract; 2019 Jun; 215(6):152413. PubMed ID: 30987832
[TBL] [Abstract][Full Text] [Related]
17. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis.
Theodorescu D; Wittke S; Ross MM; Walden M; Conaway M; Just I; Mischak H; Frierson HF
Lancet Oncol; 2006 Mar; 7(3):230-40. PubMed ID: 16510332
[TBL] [Abstract][Full Text] [Related]
18. C-reactive protein in urologic cancers.
Huang J; Baum Y; Alemozaffar M; Ogan K; Harris W; Kucuk O; Master VA
Mol Aspects Med; 2015 Nov; 45():28-36. PubMed ID: 25936279
[TBL] [Abstract][Full Text] [Related]
19. An update on the molecular pathology of urinary bladder tumors.
Yousef PG; Gabril MY
Pathol Res Pract; 2018 Jan; 214(1):1-6. PubMed ID: 29254798
[TBL] [Abstract][Full Text] [Related]
20. The application of immunohistochemical biomarkers in urologic surgical pathology.
Wilkerson ML; Lin F; Liu H; Cheng L
Arch Pathol Lab Med; 2014 Dec; 138(12):1643-65. PubMed ID: 25427043
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
